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Abstract The 110 kDa heat shock protein (HSP) (hsp110) has
been shown to be a diverged subgroup of the hsp70 family and is
one of the major HSPs in mammalian cells [1,2]. In examining
the native interactions of hsp110, we observed that it is found to
reside in a large molecular complex. Immunoblot analysis and
co-immunoprecipitation studies identified two other HSPs as
components of this complex, hsc70 and hsp25. When examined in
vitro, purified hsp25, hsp70 and hsp110 were observed to
spontaneously form a large complex and to directly interact
with one another. When luciferase was added to this in vitro
system, it was observed to migrate into this chaperone complex
following heat shock. Examination of two deletion mutants of
hsp110 demonstrated that its peptide-binding domain is required
for interaction with hsp25, but not with hsc70. The potential
function of the hsp110-hsc70-hsp25 complex is discussed.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Heat shock proteins (HSPs) are a number of conserved
proteins that can be induced in all organisms upon the expo-
sure to stress conditions like high temperature. Many of them
also function as molecular chaperones that prevent irrevers-
ible aggregation and assist protein folding or assembly. HSPs
are divided into several major families based on their size and
structure [3^6], the most well known being hsp110, hsp90,
hsp70, hsp60/GroEL, hsp40/DnaJ and the small HSPs
(sHSP, e.g. hsp25). All of these HSPs, except hsp110, have
been extensively studied and their functions in cellular pro-
cesses are broadly recognized today. Although the cloning of
the hsp110 from hamster, mouse, yeast, Arabidopsis, fungi
and a variety of other species has been recently described
[7^14], the cellular functions of hsp110 are still not under-
stood. Studies in our laboratory have been focusing on this
large stress protein. We have previously shown that hsp110 is
a signi¢cantly enlarged relative of hsp70 family, which also
contains unique sequence elements not present in the hsp70s.
We have also shown that hsp110 inhibits the aggregation of
heat-denatured proteins in a highly e⁄cient manner, sustains
denatured proteins in a folding competent state, and confers
thermotolerance when overexpressed in vivo [2]. In order to
better understand this major stress protein in mammalian
cells, its native interactions were investigated. We describe
here studies indicating that hsp110 interacts in vivo and in
vitro with two other major stress proteins, hsc70 and hsp25,
and de¢ne the domains of hsp110 involved.
2. Materials and methods
2.1. Reagents
The rabbit anti-hsp110 antibody has been characterized previously
[1]. A⁄nity-puri¢ed mouse anti-hsc70 monoclonal antibody, rabbit
anti-murine hsp25 antibody, rat anti-hsp90 antibody and rat anti-
TCP-1a monoclonal antibody, as well as recombinant hsc70 and mur-
ine hsp25, were all obtained from Stressgen Biotechnological Corp
(Victoria, Canada). Anti-His Antibody was purchased from Amer-
sham. Colon 26 tumor cells were cultured in DMEM supplemented
with 10% calf serum in a 5% CO2 incubator.
2.2. Plasmid construction and expression
Puri¢cation of recombinant His-tagged hsp110 and two deletion
mutants used here has been described elsewhere [2,15]. Brie£y, for
the construction of hsp110 mutants, primers 5P-GCTAGAG-
GATCCTGTGCATTGCAGTGTGCAATT3/3CAGCGCAAGCT-
TACTAGTCCAGGTCCATATTGA-3P (mutant #1, amino acids
375^858) and 5P-GACGACGGATCCTCTGTCGAGGCAGACAT-
GGA3/3CAGCGCAAGCTTACTAGTCCAGGTCCATATTGA-3P
(mutant #2, amino acids 508^858) were used in the polymerase chain
reaction (PCR). The PCR products were cloned into pRSETA vector
(Invitrogen), and a His6-(enterokinase recognition sequence) and ad-
ditional Asp-Arg-Trp-Gly-Ser (for mutant #1) or Asp-Arg-Trp (for
mutant #2) were added to the N-terminal of hsp110 mutants. Plas-
mids were transformed into Escherichia coli strain JM109 (DE3) and
expression products were puri¢ed by Ni2-nitrilotriacetic acid-agarose
column (QIAGEN). The protein concentration was measured using
the Bio-Rad protein assay kit.
2.3. Puri¢cation of native hsp110
Cells were washed with phosphate-bu¡ered saline (PBS) and homo-
genized with a Te£on homogenizer with ¢ve volumes of bu¡er (30 mM
NaHCO3, pH 7.5, 1 mM phenylmethylsulfonyl £uoride). The homo-
genates were centrifuged for 20 min at 12 000Ug, supernatants were
further centrifuged for 2 h at 100 000Ug. Cell extracts were ¢rst
applied to Con-A-Sepharose column, unbound proteins were collected
and loaded on ion exchange column (Mono Q, Pharmacia) equili-
brated with 20 mM Tris^HCl, pH 7.5, 200 mM NaCl, 0.1 mM dithio-
threitol (DTT). Bound proteins were eluted with a linear salt gradient
(200 mMV350 mM NaCl). hsp110 pooled fractions were concen-
trated using centricon 30 (Amicon) and applied to size exclusion col-
umn (Superose 6, Pharmacia) for high performance chromatography
equilibrated with 20 mM Tris^HCl, pH 8.0, 150 mM NaCl, 1 mM
DTT), then eluted with at a £ow rate of 0.2 ml/min. Thyroglobulin
(669 kDa), ferritin (440 kDa), catalase (158 kDa), albumin (67 kDa)
and ovalbumin (43 kDa) were used as protein markers.
2.4. Western blot analysis
Cells were washed with PBS and lysed in 50 mM Tris^HCl, pH 7.5,
150 mM NaCl, 2 mM EDTA, 1% Triton X-100 and protease inhib-
itors. After incubation on ice for 30 min, cell extracts were boiled with
an equal volume of sodium dodecyl sulfate (SDS) sample bu¡er
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(50 mM Tris^HCl, pH 6.8, 5% L-mercaptoethanol, 2% SDS, 10%
glycerol) for 10 min and centrifuged at 10 000Ug for 20 min. Equiv-
alent protein samples were subjected to 7.5^10% SDS-polyacrylamide
gel electrophoresis (PAGE) and electrotransferred onto Immobilon-P
membrane (Millipore, UK). Membranes were blocked with 5% non-
fat milk in TBST (20 mM Tris^HCl, pH 7.4, 137 mM NaCl, 0.05%
Tween-20) for 1 h at room temperature, and then incubated for 2 h
with primary antibodies diluted 1:1000 in TBST. After washing, mem-
branes were incubated with horseradish peroxidase-conjugated goat
anti-rabbit IgG or goat anti-mouse IgG diluted 1:2000 in TBST.
Immunoreactivity was detected using the enhanced chemiluminescence
detection system [16,17] (Amersham, Arlington Heights, IL, USA).
2.5. Immunoprecipitation
Immunoprecipitation was performed as previously described
[18,19]. In brief, cells were washed three times with cold PBS and
lysed in bu¡er (10 mM Tris^HCl, pH 7.4, 150 mM NaCl, 2 mM
EDTA, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP40, 10 Wg/ml
leupeptin, 25 Wg/ml aprotinin, 1 mM ABESF, 0.025% NaN3). The
lysates were centrifuged and supernatant was presorbed with 0.05
volume pre-immune serum together with 30 ml protein A beads for
1 h. The lysates were incubated overnight at 4‡C with hsp110 anti-
body (1:100) or hsc70 antibody (1:200) or hsp25 antibody (1:100).
For in vitro analysis of interaction within chaperones, recombinant
wild-type hsp110 and hsp110 mutants were ¢rst incubated with hsc70
or hsp25 at 30‡C. Then, hsc70 antibody or hsp25 antibody were
added and further incubated overnight at 4‡C. Immune complex
was precipitated with protein A-agrose (30 Wl) for 2 h. Precipitates
were washed three times with 50 mM Tris^HCl, pH 7.5, 150 mM
NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, 30^40 Wl
SDS sample bu¡er was added and boiled for 5 min. Supernatants
were loaded to 7.5^12% SDS-PAGE and analyzed by immunoblot-
ting.
2.6. Interaction between luciferase and HSPs
Luciferase (Boehringer Mannheim) was incubated with hsp110,
hsc70 and hsp25 (150 nM each) in 25 mM HEPES, pH 7.9, 5 mM
magnesium acetate, 50 mM KCl, 5 mM L-mercaptoethanol, and 1
mM ATP at room temperature or 43‡C for 30 min. The solution
was centrifuged at 16 000Ug for 20 min, the supernatant was loaded
on the Sephacryl S-300 column (Pharmacia) equilibrated with 20 mM
Tris^HCl, pH 7.8, 150 mM NaCl and 2 mM DTT. The protein was
eluted at a £ow rate of 0.24 ml/min at 4‡C. Fractions were collected
and analyzed by Western blotting.
3. Results
3.1. Existence of hsp110 as a large complex containing hsc70
and hsp25
In order to investigate the physiological role of hsp110, our
e¡orts have focused on the characterization of native hsp110
in Colon 26 cells. After cell extracts were applied to successive
chromatography on Con-A-Sepharose and Mono Q columns,
partially puri¢ed hsp110 fraction was loaded onto the Super-
ose 6 size exclusion column (maximum resolution of 5000
kDa). It was observed that the Con-A and ion exchange-pu-
ri¢ed hsp110 fraction eluted from the Superose column in
those fractions of size range between 200 and 700 kDa (Fig.
1A). Work was repeated using Sephacryl 300 (allyl dextran/
bisacrylamide matrix) column and analysis provided similar
data (data not shown).
Since hsp110 was eluted as one broad peak of high molec-
ular mass, it is reasonable that this large in situ hsp110 com-
plex might also contain additional components, potentially
including other molecular chaperones and/or cellular sub-
strates that may interact with hsp110. In order to investigate
this possibility, we examined the puri¢ed hsp110 fraction de-
rived from both ion exchange and size exclusion columns by
immunoblotting for other HSPs using available antibodies. As
shown in Fig. 1B, antibodies for hsp90, hsc70, T-complex
polypeptide 1 (TCP-1) and hsp25 were used. All four proteins
were readily detectable in the total cell lysate (lanes 1, 3, 5 and
7). When the hsp110 fraction was examined, TCP-1 and hsp90
were not observed (lanes 2 and 6). However, both hsc70 and
hsp25 were found to co-purify with hsp110 with a signi¢cantly
greater fraction of total cellular hsc70 present than of hsp25.
Having found that hsc70 and hsp25 were also present, we
determined their chromatographic pro¢les in the puri¢ed sys-
tem (also shown in Fig. 1A).
To determine whether this co-puri¢cation also re£ected an
interaction between these three molecular chaperones, a recip-
Fig. 1. Characterization of hsp110 complex. A: Chromatography pro¢les of native hsp110 separated by size exclusion column for FPLC.
hsp110 was partially puri¢ed by successive chromatography on Con-A-Sepharose and Mono Q column. Pooled fraction was loaded on the
Superose 6 column, proteins in each fraction were detected by immunoblotting with antibodies for hsp110, hsc70 and hsp25 (1:1000). B: Com-
position analysis of native hsp110 complex. Puri¢ed hsp110 fraction was detected by antibodies for hsp90 (lane 1, 2), hsc70 (lane 3, 4), TCP-1
(lane 5, 6) and hsp25 (lane 7, 8). Total cell extracts were also used as a positive control (lane 1, 3, 5 and 7).
FEBS 23160 30-12-99
X.-Y. Wang et al./FEBS Letters 465 (2000) 98^102 99
rocal co-immunoprecipitation analysis was conducted with
Colon 26 cell extracts and hsp110 fractions. Hsc70 and
hsp25 were shown to precipitate with hsp110 using an anti-
hsp110 antibody (Fig. 2A). Conversely, hsp110 was co-pre-
cipitated by an anti-hsc70 antibody or anti-hsp25 antibody
(Fig. 2B,C, top). Pre-immune serum was also used to perform
immunoprecipitation as a negative control with a correspond-
ingly negative outcome (data not shown). Finally, interaction
between hsc70 and hsp25 was analyzed by using antibodies
for hsc70 and hsp25. Again, these two proteins were observed
to co-immunoprecipitate with one (Fig. 2B,C, bottom). From
the above study, we can conclude that hsp110, hsc70 and
hsp25 interact in situ, either directly or indirectly.
3.2. Analysis of interaction of hsp110 with hsc70 and hsp25
in vitro
Next, we wished to determine whether hsp110, hsc70 and
hsp25 interacted in vitro and whether they also were capable
of forming a large molecular weight complex by using puri¢ed
protein components. We then added luciferase as a potential
substrate to this mixture since we have previously shown that
hsp110 can solublize this reporter protein following heat de-
naturation. Luciferase, with hsp110, hsc70 and hsp25 mix (at
1:1 molar ratio) were incubated at room temperature or at
43‡C for 30 min. The soluble fractions were loaded onto a
Sephacryl S-300 column, eluted fractions were run on SDS-
PAGE and analyzed by immunoblotting with antibodies for
hsp110, hsc70, hsp25 and luciferase. The results of this study
are presented in Fig. 3. It was found that hsp110, hsc70 and
hsp25 are again present in high molecule weight fractions,
however, these fractions were eluted at a signi¢cantly larger
molecular size than that seen in vivo (Fig. 3A). Moreover, it
was seen that heat treatment does not change the elution
pattern for hsp110, hsc70 or hsp25. However, luciferase,
which does not co-elute with the hsp110 complex prior to
heating (being present as a monomer), was observed to
move into a high molecule weight structure after the heat
Fig. 2. Reciprocal immunoprecipitation between hsp110 and hsp70,
hsp25. Cell lysates (lane 2) were incubated with antibodies for
hsp110 (1:100) (A), hsp70 (1:200) (B) and hsp25 (1:100) (C), pro-
tein A-Sepharose was added and further incubated at 4‡C overnight,
immunoprecipitates were examined by immunoblotting with hsp110,
hsp70 and hsp25 antibodies. Total cell extracts were also used as a
positive control (lane 1).
Fig. 3. Interaction between luciferase and HSPs complex. Luciferase and HSPs were incubated at room temperature (A) or 43‡C (B) for 30
min and soluble fraction after centrifugation at 16 000Ug was loaded on Sephacryl S-300 column. The eluted fractions were analyzed by immu-
noblotting with antibodies for HSPs and luciferase.
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exposure (Fig. 3B). Almost all of the luciferase was sustained
in a soluble form in these experiments. When heated alone,
luciferase became rapidly insoluble ([2] and data not shown).
Heat shock did not a¡ect the solubility of the three hsp110,
hsc70 or hsp25.
The above data indicate that hsp110, hsc70 and hsp25 co-
purify in a large molecular weight structure in vitro, as does
luciferase (if present) after heating. This does not indicate how
these proteins interact with themselves or that any two of
them interact at all, although, that heated luciferase remains
soluble is evidence for its interaction with at least one of the
chaperones. Speci¢cally, do both hsp110 and hsp25 bind to
hsc70 but not to one another or can hsp110 and hsp25 inter-
act on their own, etc.? To determine how these proteins in-
teract, we again performed co-immunoprecipitation experi-
ments using the pairs of puri¢ed proteins. Hsc70 and
hsp110 were found to interact in the absence of hsp25 (Fig.
4, lane 1) and correspondingly hsp110 was observed to pre-
cipitate with hsp25 alone, in the absence of hsc70 (lane 4).
Lastly, hsc70 and hsp25 also co-precipitate in the absence of
hsp110 (lane 8).
Finally, we extended this in vitro study de¢ning the inter-
actions between hsp110, hsc70 and hsp25 by examining two
deletion mutants of hsp110 which have previously been shown
to represent the most simplistic (i.e. functional and non-func-
tional) forms of this chaperone [15]. The ¢rst mutant exam-
ined (#1) lacks the N-terminal ATP-binding domain of
hsp110, but contains the remaining sequence: i.e. the adjacent
L sheet peptide-binding domain and other C-terminal sequen-
ces (size: 75 kDa and containing amino acids 375^858). This
mutant has been shown to be fully functional in its ability to
stabilize heat-denatured luciferase in a folding competent
state. The second mutant used here (#2) again lacked the
ATP-binding domain as well as the adjacent L sheet (pep-
tide-binding) domain, but contained the remaining C-terminal
sequence (size: 62 kDa and containing amino acids 508^858).
This mutant has recently been shown to be incapable of per-
forming the chaperoning function of sustaining heat-dena-
tured luciferase in a soluble state. Mutant #1 (no ATP-bind-
ing domain) was observed to co-precipitate with both hsp70
(lane 2) and hsp25 (lane 5), indicating that these interactions
do not involve its ATP-binding domain. However, mutant #2
(lacking both the ATP region and the peptide-binding region
of hsp110) was observed to only associate with hsp70 (lane 3).
This indicates that hsp25 and hsp70 can interact with hsp110
at di¡erent sites and that the association of hsp110 with hsp25
requires the peptide-binding domain of hsp110.
4. Discussion
The present study describes investigations into the native
interactions of hsp110 in Colon 26 cells. We have found
that hsp110 co-puri¢es with both hsc70 and hsp25 and fur-
ther, that the three proteins can be co-immunoprecipitated.
To determine that the co-immunoprecipitation results can re-
£ect direct interactions between these chaperones and to also
de¢ne these interactions, in vitro studies using puri¢ed
hsp110, hsc70 and hsp25 were undertaken. It was found
that these three chaperones also spontaneously form a large
molecular complex in vitro. Moreover, this complex forms in
the absence of an added substrate, but substrate (luciferase)
can be induced to migrate into the complex by a heat stress. It
is also shown that each pair of these proteins can interact
directly, i.e. hsc70 with hsp110, hsc70 with hsp25, and
hsp110 with hsp25. This, together with the co-precipitation
data obtained from cell lysates, strongly argues that these
interactions naturally occur in situ. Moreover, use of two
deletion mutants of hsp110 demonstrates that its peptide-
binding domain is required for hsp25-binding, but not for
hsc70-binding and that its ATP-binding domain is not re-
quired for the interaction with either hsc70 or hsp25. This
suggests that hsp110 may bind to hsp25 through its peptide-
binding domain. That hsc70-hsp110-binding occurs in the ab-
sence of the hsp110 peptide-binding domain suggests that
hsc70 may be actively binding to hsp110 through its (i.e.
hsc70’s) peptide-binding domain, but does not exclude the
possibility that the two proteins interact via the involvement
of other C-terminal domains.
These interactions between hsp110 and hsc70 raise ques-
tions as to how these proteins may function cooperatively.
Since the peptide-binding domain of hsc70 and hsp110 ap-
pears to represent the ‘business end’ of these chaperones in
performing chaperoning functions, it would be anticipated
that their peptide-binding domains would be actively associ-
ated with substrate and not one another. This raises the pos-
sibility that this complex represents a chaperone ‘storage com-
partment’ which awaits cellular requirements. However, the
migration of heat-denatured luciferase into this fraction fol-
lowing heat shock argues for an active chaperoning activity of
the complex itself. It is possible that hsc70 may piggy-back
hsp110 in a manner which allows transfer of substrate from
hsp110 to hsc70 with subsequent folding in conjunction with
DnaJ homologs and other chaperones. hsp110 has not yet
been shown to have a folding function in conjunction with
DnaJ co-chaperones, as is the case with hsc70 [2,15]. How-
ever, hsp110 exhibits di¡erent ATP-binding properties than
do the hsp70s [15] and possible co-chaperones of hsp110
may be awaiting discovery. Previous in vitro studies have
demonstrated that while sHSPs (e.g. hsp25) bind non-native
protein [20^23], refolding still requires the presence of hsp70
[24]. Perhaps, hsp110 and sHSPs may act in the di¡erential
binding of a broad variety of substrates for subsequent shut-
Fig. 4. Interaction analysis of hsp110 mutants and hsp70, hsp25 in
vitro. E. coli expressed full-length hsp110 (lane 1, 4) and mutant #1
(lane 2, 5), mutant #2 (lane 3, 6) were incubated with hsc70 or
hsp25 at 30‡C for 1 h, then anti-hsc70 or anti-hsp25 antibodies
were added. Immunoprecipitates were detected by anti-His antibody.
In vitro interaction between hsc70 and hsp25 was also analyzed by
the same method described above, hsc70 antibodies were used to
test immunoprecipitate (lane 8). Total cell lysate was used as a posi-
tive control (lane 7). Equal amounts of protein (2 Wg) for wild-type
hsp110, hsp110 mutants, hsc70 and hsp25 were included in each as-
say.
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tling to hsp70-DnaJ containing chaperone machines. Studies
indicate, however, that an in vitro hsp110-hsc70-hsp25 com-
plex (at a 1:1:1 molar ratio) is slightly less e¡ective than is
hsp110 alone in inhibiting luciferase aggregation following
heat shock and further studies of this nature are necessary
to determine or exclude a direct chaperoning function
(Wang et al., data not shown).
That these three chaperones interact may represent a gen-
eral phenomenon. Plesofsky-Vig and Brambl have recently
shown that the small HSP of Neurospora crassa, called
hsp30, binds to two cellular proteins, hsp70 and hsp88. Clon-
ing and analysis of hsp88 have shown that it represents the
hsp110 of N. crassa [25], suggesting that the interactions de-
scribed here are phylogenetically conserved. In addition,
Hatayama has described an interaction between hsp110 (re-
ferred to as hsp105) and hsp70 in FM3A cells [26]. The size of
the hsp110 complex and the interaction with hsc70 observed
in the present study (which also employed the added step of
ion exchange chromatography) are clearly similar to, and in
excellent agreement with this recent report. That hsp110 and
hsc70 interact is also suggested by earlier studies from our
laboratory which have demonstrated that hsp110 and hsc70
can interact and are functional in the folding heat-denatured
luciferase [2]. Finally, it is noteworthy that hsp90 and TCP-1
were not observed in the hsp110 complex in the present study,
despite its previously identi¢ed association with hsc70 and
other proteins in the steroid hormone receptor [27^31]. How-
ever, it has recently been shown that SSE1 encoding a yeast
member of the hsp110 family is required for the function of
glucocorticoid receptor and physically associates with the
hsp90 [32].
Several important questions are raised by the observations
described here. For example, does this complex o¡er an en-
hanced capacity to hold a greater variety of substrate proteins
in a folding competent state and/or to do so more e⁄ciently,
and is there an enhanced ability gained to refold denatured
proteins in the presence of additional chaperones? Further
studies are needed to de¢ne the function(s) of this hsp110-
hsc70-hsp25 complex and how these chaperones interact
with one another in the processing of substrate.
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